Profectus BioSciences presents pre-clinical filovirus vaccine data

Profectus BioSciences presents pre-clinical filovirus vaccine data.

Profectus BioSciences recently presented pre-clinical data on its VesiculoVax vector platform vaccine candidate, which is designed to protect against filoviruses such as Marburg and Ebola.

Profectus Chief Scientific Officer John Eldridge presented the findings, which show that the vaccine offers immunogenicity and is considered safe for use. In its findings, the company also found that the multi-component vaccines provide protection against low-passage filovirus isolates, used as reference strains.

The candidate combines three vectors and aims to provide protection against any strain of the Ebola or Marburg viruses. This vaccine candidate is supported financially by the Department of Defense’s Joint Vaccine Acquisition Program (JVAP), the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA).

"We have worked for several years to develop a single vaccine to protect against all the filoviruses," Eldridge said. "In addition to the 2014 outbreak of Ebola virus Zaire in West Africa, outbreaks of both Marburg virus and Ebola virus Sudan have occurred recently and underscore the need for a vaccine that provides broad protection against all filovirus strains. These results demonstrate that the components of the VesiculoVax trivalent Ebola/Marburg vaccine do not interfere with each other and work together to provide the needed breadth of protection."

Organizations in this story

Profectus BioSciences 6411 Beckley St Baltimore, MD 21224

National Institutes of Health 9000 Rockville Pike Bethesda, MD 20892

Get notified the next time we write about any of these organizations!